SCHEMBL2835907

SCHEMBL2835907

COc1cc(C)c(S(=O)(=O)N2CCCCC2COc2ccnc(N3CCCN(Cc4ccccn4)CC3)n2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
KDM4E B2RXH2 6/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
POLB P06746 2/20 0.36
MAPK1 P28482 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
GAA P10253 1/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835615 0.98 ALDH1A1 (0.40) ALDH1A1KDM4EL3MBTL1NPSR1POLB
SCHEMBL2836786 0.89 KMT2A (0.39) ALDH1A1KDM4EL3MBTL1MAPK1KMT2A
SCHEMBL2832996 0.86 KMT2A (0.40) ALDH1A1KDM4EMAPK1KMT2ALMNA
SCHEMBL2836548 0.85 CA12 (0.38) ALDH1A1KDM4EL3MBTL1MEN1KMT2A
SCHEMBL2835301 0.84 CASP3 (0.38) ALDH1A1KDM4ELMNAMAPTHSD17B10
SCHEMBL2836644 0.84 CASP3 (0.38) ALDH1A1KDM4ELMNAMAPTHSD17B10
SCHEMBL2837335 0.83 BDKRB1 (0.41) HTR2AHTR2CCA12CA1CA2
SCHEMBL2839870 0.83 HTR7 (0.38) ALDH1A1KDM4EHTR2ACHRM4CASP3
SCHEMBL2836146 0.83 CASP3 (0.39) ALDH1A1KDM4EKMT2AMAPTCA12
SCHEMBL2830936 0.83 ALDH1A1 (0.40) ALDH1A1KDM4EL3MBTL1NPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS ALDH1A1 2375/4885KDM4E 3383/4885L3MBTL1 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.